Ngeow Joanne, Tan Iain Beehuat, Choo Su Pin
Department of Medical Oncology, National Cancer Centre, Singapore.
Asia Pac J Clin Oncol. 2011 Sep;7(3):224-35. doi: 10.1111/j.1743-7563.2011.01407.x.
Gastric cancer (GC) constitutes a major cause of cancer deaths worldwide. Recent improvements in both surgical techniques and adjuvant and neoadjuvant radiotherapy and chemotherapy approaches have increased the survival of patients with loco-regional disease. However most patients with GC have advanced disease either at diagnosis or at follow up. Despite recent advances in the treatment of advanced disease, these patients still have poor outcomes. An emerging understanding of the molecular pathways that characterize cell growth, cell cycle, apoptosis, angiogenesis and invasion has provided novel targets in cancer therapy. In this review we describe the current status of targeted therapies in the treatment of GC. These therapeutic strategies include epidermal growth factor receptor inhibitors, antiangiogenic agents, cell cycle inhibitors, apoptosis, promoters and matrix metalloproteinases inhibitors.
胃癌（GC）是全球癌症死亡的主要原因之一。近期手术技术以及辅助和新辅助放疗与化疗方法的改进提高了局部区域疾病患者的生存率。然而，大多数GC患者在诊断时或随访时已处于晚期疾病状态。尽管晚期疾病的治疗最近取得了进展，但这些患者的预后仍然很差。对细胞生长、细胞周期、凋亡、血管生成和侵袭等分子途径的新认识为癌症治疗提供了新的靶点。在本综述中，我们描述了GC治疗中靶向治疗的现状。这些治疗策略包括表皮生长因子受体抑制剂、抗血管生成药物、细胞周期抑制剂、凋亡诱导剂和基质金属蛋白酶抑制剂。
